New Research Links Dental Amalgam Mercury Fillings To Arthritis.

New research links arthritis to dental amalgam fillings. These silver-colored fillings are 50% mercury and are still used in, often in disadvantaged children and adults.

In this new study, researchers David and Mark Geier report on a significant relationship between the number of dental amalgam filling surfaces and diagnoses of arthritis. They find that incidences of arthritis peak among adults with 4 to 7 dental amalgam filling surfaces.

It is important to note that the number of surfaces is not the same as the number of fillings. Each tooth has five surfaces, which means that a person with only one filling could have up to five surfaces.

The authors examined data from the 2015-2016 National Health and Nutrition Examination Survey (NHANES) including demographics, dental exams, and arthritis diagnoses. Data about the patient’s type of dental filling recently became accessible. With this information, the researchers were able to discover higher incidences of arthritis in people with silver-colored mercury amalgam fillings than those with other fillings such as tooth-colored composites.

All dental amalgams are silver-colored and contain about 50% mercury. These fillings are still being used in the U.S. even though they have been associated with health risks.

In September 2020, the Food and Drug Administration (FDA) updated risks of dental amalgam fillings for susceptible groups. However, arthritis was not specifically mentioned when the FDA warned of “harmful health effects of mercury vapor released from the device.”

The groups that FDA advised to avoid getting dental amalgam fillings include pregnant women; women planning to become pregnant; nursing women and their newborns and infants; children; people with neurological disease such as multiple sclerosis, Alzheimer’s disease or Parkinson’s disease; people with impaired kidney function; and people with known heightened sensitivity (allergy) to mercury or other components of dental amalgam.

FDA is currently open for comments on how information about medical devices including dental amalgam fillings should be shared with patients and providers.

“Mercury is continually off-gassed from dental amalgam fillings,” explains David Kennedy, DDS, Past IAOMT President. “With the Geiers’ new research joining the ranks of thousands of other studies, it is abundantly clear that mercury from amalgams poses a danger to everyone, including patients, dentists, and dental employees.”

The Geiers’ study was partially funded by the IAOMT, a non-profit organization that evaluates biocompatibility of dental products, including mercury filling risks.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

How a Study Became a Regulatory Benchmark – and Why the Ground Has Shifted

In 2006, FDA staff prepared a White Paper concerning potential adverse health risks associated with mercury in dental amalgam. The agency then brought the issue before a joint advisory panel in September 2006. The panel did not simply endorse the FDA staff’s conclusion. According to the contemporaneous record, the panel voted 13–7 against accepting the FDA staff’s safety conclusion.

Learn More »

The Evidence That Never Made the Headlines: Revisiting the Casa Pia Mercury Trial

One of the most important documents I obtained through the Freedom of Information Act is a September 15, 1999 Report to the Data and Safety Monitoring Board for the Casa Pia Children’s Amalgam Trial. This document was written while the trial was still underway. It is not a retrospective interpretation. It is a contemporaneous report from the investigators to the body charged with monitoring the safety of the study.

Learn More »